Department of Human Biology, Nutrition and Toxicology Research Institute Maastricht, Maastricht University, The Netherlands.
Br J Nutr. 2011 Dec;106(11):1757-62. doi: 10.1017/S0007114511002194. Epub 2011 Jun 17.
In rats, oligofructose has been shown to stimulate satiety hormone secretion, reduce energy intake and promote weight loss. The present study aimed to examine the effect of oligofructose supplementation on appetite profiles, satiety hormone concentrations and energy intake in human subjects. A total of thirty-one healthy subjects (ten men and twenty-one women) aged 28 (SEM 3) years with a BMI of 24·8 (SEM 0·3) kg/m(2) were included in a randomised double-blind, cross-over study. The subjects received 10 g oligofructose, 16 g oligofructose or 16 g placebo (maltodextrin) daily for 13 d, with a 2-week washout period between treatments. Appetite profile, active glucagon-like peptide 1 (GLP-1) and peptide YY3-36 (PYY) concentrations and energy intake were assessed on days 0 and 13 of the treatment period. Time × treatment interaction revealed a trend of reduction in energy intake over days 0-13 by oligofructose (P = 0·068). Energy intake was significantly reduced (11 %) over time on day 13 compared with day 0 with 16 g/d oligofructose (2801 (SEM 301) v. 3217 (SEM 320) kJ, P < 0·05). Moreover, energy intake was significantly lower with 16 g/d oligofructose compared with 10 g/d oligofructose on day 13 (2801 (SEM 301) v. 3177 (SEM 276) kJ, P < 0·05). Area under the curve (AUC) for GLP-1 on day 13 was significantly higher with 16 g/d oligofructose compared with 10 g/d oligofructose (45 (SEM 4) v. 41 (SEM 3) pmol/l × h, P < 0·05). In the morning until lunch, AUC(0-230 min) for PYY on day 13 was significantly higher with 16 g/d oligofructose compared with 10 g/d oligofructose and placebo (409 (SEM 35) v. 222 (SEM 19) and 211 (SEM 20) pg/ml × h, P < 0·01). In conclusion, 16 g/d and not 10 g/d oligofructose may be an effective dose to reduce energy intake, possibly supported by higher GLP-1 and PYY concentrations.
在大鼠中，低聚果糖已被证明可刺激饱腹感激素的分泌，减少能量摄入并促进体重减轻。本研究旨在探讨低聚果糖补充对人体食欲特征、饱腹感激素浓度和能量摄入的影响。共有 31 名健康受试者（10 名男性和 21 名女性），年龄为 28 岁（SEM 3），BMI 为 24.8（SEM 0.3）kg/m2，被纳入一项随机、双盲、交叉研究。受试者每天接受 10 g 低聚果糖、16 g 低聚果糖或 16 g 安慰剂（麦芽糊精），治疗期之间有 2 周的洗脱期。在治疗期的第 0 天和第 13 天评估了食欲特征、活性胰高血糖素样肽 1（GLP-1）和肽 YY3-36（PYY）浓度和能量摄入。时间×处理的相互作用显示出低聚果糖在第 0-13 天的能量摄入呈下降趋势（P=0.068）。与第 0 天相比，第 13 天 16 g/d 低聚果糖的能量摄入明显减少（2801（SEM 301）v. 3217（SEM 320）kJ，P<0.05）。此外，与第 10 天相比，第 13 天 16 g/d 低聚果糖的能量摄入明显降低（2801（SEM 301）v. 3177（SEM 276）kJ，P<0.05）。第 13 天时，16 g/d 低聚果糖的 GLP-1 曲线下面积（AUC）明显高于 10 g/d 低聚果糖（45（SEM 4）v. 41（SEM 3）pmol/l×h，P<0.05）。在第 13 天的早晨到午餐时间，16 g/d 低聚果糖的 PYY 的 AUC（0-230 min）明显高于 10 g/d 低聚果糖和安慰剂（409（SEM 35）v. 222（SEM 19）和 211（SEM 20）pg/ml×h，P<0.01）。总之，16 g/d 而不是 10 g/d 的低聚果糖可能是减少能量摄入的有效剂量，这可能是由于 GLP-1 和 PYY 浓度较高所致。
